MA27898A1 - Formulation pharmaceutique - Google Patents

Formulation pharmaceutique

Info

Publication number
MA27898A1
MA27898A1 MA28702A MA28702A MA27898A1 MA 27898 A1 MA27898 A1 MA 27898A1 MA 28702 A MA28702 A MA 28702A MA 28702 A MA28702 A MA 28702A MA 27898 A1 MA27898 A1 MA 27898A1
Authority
MA
Morocco
Prior art keywords
formulation
pharmaceutical formulation
amount
weight
total weight
Prior art date
Application number
MA28702A
Other languages
English (en)
Inventor
Konieczna Malgorzata
Krohn Heiner
Roman Wanda
Schlehahn Hendrik
Anna Strozyk Malgorzata
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27898A1 publication Critical patent/MA27898A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il est proposé une formulation pharmaceutique stable comprenant (a) une quantité efficace de lévothyroxine sodique, (b) de la cellulose microcristalline qui a un diamètre moyen de particule inférieur à 125 Ám et qui est présente en une quantité de 60 à 85 % en poids/poids sur la base du poids total de la formulation et (c) de l'amidon prégélétanisé présent en une quantité de 5 à 30 % en poids/poids sur la base du poids total de la formulation. Il est proposé également un procédé pour la préparation d'une telle formulation.
MA28702A 2003-07-10 2006-01-06 Formulation pharmaceutique MA27898A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316206.2A GB0316206D0 (en) 2003-07-10 2003-07-10 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MA27898A1 true MA27898A1 (fr) 2006-05-02

Family

ID=27741962

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28702A MA27898A1 (fr) 2003-07-10 2006-01-06 Formulation pharmaceutique

Country Status (28)

Country Link
US (1) US7955621B2 (fr)
EP (1) EP1643976B1 (fr)
JP (2) JP4880457B2 (fr)
KR (1) KR101136655B1 (fr)
CN (1) CN100430051C (fr)
AR (1) AR045719A1 (fr)
AT (1) ATE415949T1 (fr)
AU (1) AU2004255466B2 (fr)
BR (1) BRPI0412391B8 (fr)
CA (1) CA2531853C (fr)
CO (1) CO5700710A2 (fr)
DE (1) DE602004018142D1 (fr)
DK (1) DK1643976T3 (fr)
ES (1) ES2319193T3 (fr)
GB (1) GB0316206D0 (fr)
IL (1) IL172619A (fr)
IS (1) IS2616B (fr)
MA (1) MA27898A1 (fr)
MX (1) MXPA06000353A (fr)
MY (1) MY140127A (fr)
NO (1) NO338465B1 (fr)
NZ (1) NZ544174A (fr)
PL (1) PL1643976T3 (fr)
PT (1) PT1643976E (fr)
RU (1) RU2349345C2 (fr)
TW (1) TWI329026B (fr)
WO (1) WO2005004849A2 (fr)
ZA (1) ZA200510224B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
CA2634993A1 (fr) * 2006-01-06 2007-07-12 Intervet International B.V. Composition d'hormone thyroidienne liquide concentree
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
US9271951B2 (en) 2012-12-21 2016-03-01 Mylan Inc. Levothyroxine formulation with acacia
WO2014098887A1 (fr) * 2012-12-21 2014-06-26 Mylan Inc. Formulation de lévothyroxine avec de la gomme arabique
WO2014098886A1 (fr) * 2012-12-21 2014-06-26 Mylan Inc. Formulation de lévothyroxine avec de la carraghénine
EP2932963A1 (fr) 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stables firmes galéniques contenant du Lévothyroxine de Sodium
KR102488488B1 (ko) 2015-10-07 2023-01-12 쿄와 기린 가부시키가이샤 아릴알킬아민 화합물 함유 의약 조성물
JP6168673B2 (ja) 2015-10-07 2017-07-26 協和発酵キリン株式会社 アリールアルキルアミン化合物含有医薬組成物
US20200046664A1 (en) 2016-10-10 2020-02-13 Ftf Pharma Private Limited Method for preparation of liquid oral composition of l-thyroxin
SG11201906890TA (en) * 2017-02-03 2019-08-27 Berlin Chemie Ag Oral thyroid therapeutic agent
IT201800003615A1 (it) * 2018-03-15 2019-09-15 Altergon Sa Formulazioni altamente stabili di ormone tiroideo in capsule molli
CN109988076A (zh) * 2019-05-05 2019-07-09 上海葆隆生物科技有限公司 一种左甲状腺素钠杂质及其制备
KR20220085086A (ko) 2020-12-14 2022-06-22 메디케어제약 주식회사 갑상선 기능 저하증을 동반한 대사 증후군을 치료하는 약제학적 복합제제
WO2025181833A1 (fr) * 2024-03-01 2025-09-04 Srushti Pharmaceuticals Pvt Ltd Composition à base de pastilles de sodium de lévothyroxine et procédé de préparation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
CA2145171C (fr) * 1992-09-22 1999-09-21 Thomas A. Ruszkay Produit et methode pour l'obtention de cellulose microcristalline
GB9401879D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
DE19541128C2 (de) * 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
DE69633018T2 (de) * 1995-11-14 2004-12-09 Abbott Gmbh & Co. Kg Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
JPH11286456A (ja) 1998-03-31 1999-10-19 Lion Corp 複合粉体組成物及び錠剤
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP3435664B2 (ja) 1999-12-08 2003-08-11 ヤンセンファーマ株式会社 口腔内速崩壊型錠剤及びその製造方法
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts

Also Published As

Publication number Publication date
ES2319193T3 (es) 2009-05-05
IS2616B (is) 2010-04-15
WO2005004849A3 (fr) 2005-05-06
MY140127A (en) 2009-11-30
DK1643976T3 (da) 2009-04-06
EP1643976A2 (fr) 2006-04-12
CN100430051C (zh) 2008-11-05
BRPI0412391B1 (pt) 2017-10-31
IS8287A (is) 2006-02-07
PL1643976T3 (pl) 2009-05-29
CA2531853A1 (fr) 2005-01-20
IL172619A0 (en) 2006-04-10
CO5700710A2 (es) 2006-11-30
NZ544174A (en) 2008-07-31
HK1089094A1 (en) 2006-11-24
ZA200510224B (en) 2007-09-26
KR101136655B1 (ko) 2012-04-18
RU2006104009A (ru) 2006-06-27
BRPI0412391B8 (pt) 2021-05-25
CA2531853C (fr) 2010-09-14
US7955621B2 (en) 2011-06-07
KR20060065628A (ko) 2006-06-14
AU2004255466A1 (en) 2005-01-20
NO20060208L (no) 2006-01-13
AR045719A1 (es) 2005-11-09
WO2005004849A2 (fr) 2005-01-20
TWI329026B (en) 2010-08-21
ATE415949T1 (de) 2008-12-15
TW200518785A (en) 2005-06-16
NO338465B1 (no) 2016-08-22
DE602004018142D1 (de) 2009-01-15
EP1643976B1 (fr) 2008-12-03
JP2009513530A (ja) 2009-04-02
IL172619A (en) 2010-12-30
RU2349345C2 (ru) 2009-03-20
AU2004255466B2 (en) 2007-07-26
MXPA06000353A (es) 2006-03-28
JP4880457B2 (ja) 2012-02-22
GB0316206D0 (en) 2003-08-13
US20070110803A1 (en) 2007-05-17
JP2011213736A (ja) 2011-10-27
PT1643976E (pt) 2009-03-03
BRPI0412391A (pt) 2006-09-19
CN1819820A (zh) 2006-08-16

Similar Documents

Publication Publication Date Title
MA27898A1 (fr) Formulation pharmaceutique
CA2071408C (fr) Comprime matriciel permettant la liberation prolongee d'indapamine apres administration par voie orale
MA26702A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
EA199700110A1 (ru) Композиция с высоким содержанием ацетаминофена для прямого прессования
EA200000245A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
CA2273420C (fr) Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale
DK0869772T3 (da) Bioadhæsiv fast doseringsform
MA27624A1 (fr) Procede pour realiser une preparation enrobee
EP0299877B1 (fr) Comprimés de type à matrice hydrophile à base de salbutamol et leur procédé de préparation
ATE232087T1 (de) Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
RU2003101321A (ru) Композиции, содержащие альфа-2-адренергические агонисты
EA200300999A1 (ru) Хронотерапевтические дозированные формы
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
FI973452A7 (fi) Nauhoitettu annosmuoto aktiivisen aineen pidennettyyn jakamiseen
CA2312545A1 (fr) Composition pharmaceutique solide thermoformable a liberation controlee
RU95104236A (ru) Фармацевтическая композиция
EA200000487A1 (ru) Композиция пролонгированного высвобождения
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
TNSN03106A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuse uniforme
RU2002123182A (ru) Содержащая ибупрофен композиция
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
MA31006B1 (fr) Composition a liberation prolongee et procede de production correspondant
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
Whittle et al. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase
EE05085B1 (et) Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks